Non-melanoma skin cancers in ruxolitinib-treated MPN patients behave aggressively, with adverse features and high recurrence. In our cohort, mortality from metastatic NMSC exceeded that from myelofibrosis . Vigilant skin assessment, counselling on NMSC risks, and prospective ruxolitinib-NMSC studies are crucial.